Thalidomide and rituximab in Waldenstrom macroglobulinemia

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597120/
https://ncbi.nlm.nih.gov/pubmed/18713945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-150854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados